5 Papers
22 Citations
Deepa Anand is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Targeted therapy & BAP1. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
Vivek Subbiah,Caitlin McMahon,Shreyaskumar Patel,Ralph Zinner,Elvio G. Silva,Julia A. Elvin,Ishwaria Mohan Subbiah,Chimela Ohaji,Dhakshinamoorthy Ganeshan,Deepa Anand,Charles F Levenback,Jenny Berry,Tim Brennan,Juliann Chmielecki,Zachary R. Chalmers,John Mayfield,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross,Siraj M. Ali +19 more
TL;DR: This case represents the first report of clinical response to targeted therapy in a tumor harboring a DCTN1-ALK fusion protein, and can identify clinical relevant genomic alterations that both direct treatment targeted therapy and help discriminate between similar diagnostic entities.
BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype
Humaid O. Al-Shamsi,Deepa Anand,Rachna T. Shroff,Apurva Jain,Mingxin Zuo,Claudius Conrad,Jean Nicolas Vauthey,Milind Javle +7 more
TL;DR: BAP1 mutation in CCA may be associated with aggressive disease and poor response to standard therapies and BAP1-targeted therapies need to be investigated.
BAP1 mutation-associated cholangiocarcinoma: An aggressive disease.
Deepa Anand,Chaitanya Churi,Asif Rashid,Rachna T. Shroff,Mingxin Zuo,Claudius Conrad,Jean Nicolas Vauthey,Milind Javle +7 more
TL;DR: This work investigated the clinico-pathologic features and treatment outcomes of these patients treated at a single center with BAP1 mutation associated CCA, which is commonly mutated in uveal melanoma, mesothelioma and renal cancers.
2
Ongoing Screening and Treatment to Potentially Reduce Tyrosine Kinase Inhibitor-Related Fatigue in Renal Cell Carcinoma.
Deepa Anand,Carmen P. Escalante +1 more
TL;DR: TKI-related CRF in patients with RCC is a highly distressing complication of cancer therapy and can substantially influence drug compliance, the ability to maximally treat, and quality of life.
Current update on primary pancreatic lymphoma
TL;DR: The computed tomography, magnetic resonance imaging, and positron emission tomography findings of primary and secondary pancreatic lymphomas are reviewed and the role of endoscopic ultrasound-guided fine needle aspiration in diagnosis and management is discussed.